Congress demands documents from FDA on controversial approval of Biogen’s Alzheimer’s drug

(By Rachel Cohrs for STAT)

WASHINGTON — Lawmakers have requested data and documents from the Food and Drug Administration related to the agency’s controversial accelerated approval of Biogen’s new Alzheimer’s drug Aduhelm.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org